PRLog (Press Release)
- Aug. 24, 2010 -
PWRM had just recently has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer – NYSE: PFE), Exelon (Rivastigmine, Novartis – NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene. PWRM’s NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, PWRM’s NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.
Astro-Med, Inc. (NASDAQ: ALOT) reports net income of $323,000, equal to 4 cents per diluted share, on sales of $17,753,000 for the Second Quarter ended July 31, 2010. The Company reported net income of $585,000, equal to 8 cents per diluted share, on sales of $16,416,000 for the comparable period of the prior year. Unfavorable foreign exchange currency rates lowered this year's Second Quarter sales by approximately $227,000, or 1.4%, when compared to the previous year.
For the six months ended July 31, 2010, Astro-Med, Inc. reported net income of $753,000, equal to 10 cents per diluted share, on sales of $34,830,000. During the comparable six-month period of the prior year, net income was $354,000, equal to 5 cents per diluted share, on sales of $31,093,000.
The Company's balance sheet remains strong with a cash and marketable securities position of $21,933,000, a current ratio of 6.3:1, and zero debt.
Natus Medical Incorporated (Nasdaq:BABY)
reported in one of their most recent press releases that it has received a significant purchase order from the Kingdom of Saudi Arabia for the Company's newborn care products.
The order, which is valued at over $2.7 million, was received from the Company's distribution partner working with the Saudi Ministry of Health. The order is for ALGO newborn hearing screeners, Cool-Cap selective head-cooling devices, and Olympic Cerebral Function Monitors (CFM). The order is expected to ship by the end of the year.
Sign up for free stock alerts at http://www.pennygovernance.com/
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyGovernance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyGovernance.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur.(read more @ http://pennygovernance.com/
disclaimer) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)